Trial Profile
Phase1 Study of GR121167 - A Double Blind, Placebo Controlled, Randomized, Dose Ascending, Single and Multiple Dose Study to Investigate the Safety and Pharmacokinetics Following Intravenous Administration of GR121167 in Healthy Japanese Males-
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Zanamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 08 Sep 2011 New trial record